Shares of Plus Therapeutics Inc. (PSTV) are having a good Friday, continuing their momentum after the company announced some encouraging regulatory news earlier this week. The U.S. Food and Drug Administration (FDA) on Wednesday granted Orphan Drug Designation for its investigational therapy Reyobiq for pediatric malignant gliomas. That's a fancy way of saying the FDA recognizes this as a treatment for a rare disease—in this case, a particularly nasty form of pediatric brain cancer.

For a clinical-stage pharmaceutical company like Plus Therapeutics, which is developing targeted radiotherapeutics for difficult-to-treat central nervous system cancers, this kind of designation is a big deal. It's not an approval, but it's a significant step that comes with perks. The main one is seven years of market exclusivity if the drug eventually gets the green light. The designation is also notable because it specifically includes pediatric ependymoma, broadening the potential patient population for Reyobiq.

So what is Reyobiq? It's an investigational injectable radiotherapy (its full name is rhenium Re186 obisbemeda, but let's stick with Reyobiq) designed to deliver a targeted, high-dose radiation punch directly to tumors in the brain and spine. The idea is to hit the cancer hard while trying to spare the surrounding healthy tissue—a common challenge in treating brain tumors.

This orphan drug news isn't happening in a vacuum. It builds on other recent regulatory and clinical progress for the therapy. The company has completed a Type B meeting with the FDA supporting development plans for leptomeningeal metastases (cancer that has spread to the membranes surrounding the brain and spinal cord). There's also encouraging data from the ReSPECT-LM trial, and Phase 1 and Phase 2 studies are moving forward. Separately, the FDA has cleared an Investigational New Drug application to evaluate Reyobiq in pediatric patients with high-grade glioma and ependymoma.

In another piece of supportive news this week, Plus Therapeutics said the American Medical Association approved a new, dedicated billing code for its CNSide Cerebrospinal Fluid Tumor Cell Enumeration test. This diagnostic test helps detect tumor cells in spinal fluid. The new Proprietary Laboratory Analyses code, effective July 1, is intended to help with reimbursement, which is always a critical piece of the puzzle in healthcare.

Now, let's talk about the stock. At $5.24, the share price was up a hefty 33.67% on Friday, according to market data. But here's where it gets interesting from a chart-watcher's perspective. The stock is trading right at its 20-day simple moving average, which technical analysts might see as a potential short-term pivot point. However, it's still sitting about 17% below its 50-day moving average, suggesting the intermediate-term trend hasn't fully turned positive yet.

The relative strength index (RSI) is around 35, which is generally considered neutral territory—not overbought, not oversold. It's worth remembering the context: despite today's pop, the stock is down about 74% over the past 12 months. For traders, key levels to watch might be resistance around $6.00 and support near $5.00.

So, the story here is a clinical-stage biotech getting a regulatory nod that validates its path forward for a treatment targeting a devastating pediatric disease. The market is cheering the news today, but as always with early-stage drug developers, the real test—and the bigger potential payoff—lies ahead in the clinic.